Form 4: Aileron Therapeutics Director Josef H. von Rickenbach Granted Stock Options

Director Josef H. von Rickenbach of Aileron Therapeutics, Inc. was granted stock options on February 28, 2024.

Summary

• Josef H. von Rickenbach, a director of Aileron Therapeutics, Inc., filed a Form 4 on March 1, 2024, reporting a transaction.
• On February 28, 2024, von Rickenbach was granted stock options to purchase 2,725 shares of Aileron Therapeutics common stock at an exercise price of $4.80 per share.
• The options vest in full on the earlier of February 28, 2025, or the date of the Issuer's 2024 Annual Meeting of Stockholders.
• Following the transaction, von Rickenbach directly owns 2,725 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially incentivizing value creation.

Key Dates